Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Researchers from University of Connecticut, Health Center provide details of new studies and findings in the area of cancer gene therapy
June 17th, 2008
A new study, 'Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1,' is now available. "Progesterone (P4) influences ovarian cancer cells by an unknown mechanism. The objective was to determine whether P4 acts through progesterone receptor membrane component-1 (PGRMC1) in ovarian cancers," scientists in the United States report. "AND PATIENTS: Archival tissue and cDNA provided by OriGene were used for expression studies. In vitro experiments were conducted with Ovcar-3 cells. PCR, Western blot, and immunohistochemistry were used to measure expression of PGRMC1 and nuclear progesterone receptor (PGR)....
Source: Cancer Weekly (2008-06-17)
|
